TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The type II transmembrane serine proteases TMPRSS2 and HAT can cleave and activate the spike protein (S) of the severe acute respiratory syndrome coronavirus (SARS-CoV) for membrane fusion. In addition, these proteases cleave the viral receptor, the carboxypeptidase angiotensin-converting enzyme 2 (ACE2), and it was proposed that ACE2 cleavage augments viral infectivity. However, no mechanistic insights into this process were obtained and the relevance of ACE2 cleavage for SARS-CoV S protein (SARS-S) activation has not been determined. Here, we show that arginine and lysine residues within ACE2 amino acids 697 to 716 are essential for cleavage by TMPRSS2 and HAT and that ACE2 processing is required for augmentation of SARS-S-driven entry by these proteases. In contrast, ACE2 cleavage was dispensable for activation of the viral S protein. Expression of TMPRSS2 increased cellular uptake of soluble SARS-S, suggesting that protease-dependent augmentation of viral entry might be due to increased uptake of virions into target cells. Finally, TMPRSS2 was found to compete with the metalloprotease ADAM17 for ACE2 processing, but only cleavage by TMPRSS2 resulted in augmented SARS-S-driven entry. Collectively, our results in conjunction with those of previous studies indicate that TMPRSS2 and potentially related proteases promote SARS-CoV entry by two separate mechanisms: ACE2 cleavage, which might promote viral uptake, and SARS-S cleavage, which activates the S protein for membrane fusion. These observations have interesting implications for the development of novel therapeutics. In addition, they should spur efforts to determine whether receptor cleavage promotes entry of other coronaviruses, which use peptidases as entry receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 2×
“The program ImageJ (46) was employed for signal quantification.”
MethodAngiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Efficient selection for high-expression transfectants with a novel eukaryotic vector
Hitoshi, N., Ken-ichi, Y., & Jun-ichi, M. (1991) · Gene · doi:10.1016/0378-1119(91)90434-d · Cited by 5,134
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., Wang, H., Crameri, G., Hu, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,560
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · cited 2×
“Finally, our results should stimulate efforts to determine whether receptor proteolysis impacts infection by hCoV-229E and MERS-CoV, which, like SARS-CoV, use peptidases as receptors (54, 63) and are activated by TTSPs (64, 65).”
Background
Cited by
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Huang, Y., Yang, C., Xu, X.-F., Xu, W., & Liu, S.-W. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0485-4 · Cited by 2,224
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04474-x · Cited by 1,146
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897
“, 2013), TMPRSS2 (Heurich et al., 2014), Gal4-TurboGFP-Luc and Vp16-Gal4 (Hörnich et al.”
Self-citationChan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far
Rabi, F. A., Al Zoubi, M. S., Kasasbeh, G. A., Salameh, D. M., & Al-Nasser, A. D. (2020) · Pathogens · doi:10.3390/pathogens9030231 · Cited by 775
SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography
Klein, S., Cortese, M., Winter, S. L., Wachsmuth-Melm, M., Neufeldt, C. J., Cerikan, B., Stanifer, M. L., Boulant, S., Bartenschlager, R., & Chlanda, P. (2020) · Nature Communications · doi:10.1038/s41467-020-19619-7 · Cited by 731
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19
Zhang, S., Liu, Y., Wang, X., Yang, L., Li, H., Wang, Y., Liu, M., Zhao, X., Xie, Y., Yang, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00954-7 · Cited by 657
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., & Nagata, N. (2019) · Journal of Virology · doi:10.1128/jvi.01815-18 · Cited by 618
Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond
Lu, G., Wang, Q., & Gao, G. F. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.06.003 · Cited by 607
Shi, Y., Wang, G., Cai, X.-P., Deng, J.-W., Zheng, L., Zhu, H.-H., Zheng, M., Yang, B., & Chen, Z. (2020) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b2000083 · Cited by 580
Zhao, M.-M., Yang, W.-L., Yang, F.-Y., Zhang, L., Huang, W.-J., Hou, W., Fan, C.-F., Jin, R.-H., Feng, Y.-M., Wang, Y.-C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00558-8 · Cited by 515
Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Li, Z., Cui, X., Xiao, J., Zhan, J., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320953 · Cited by 498
ACE2: The Major Cell Entry Receptor for SARS-CoV-2
Scialo, F., Daniele, A., Amato, F., Pastore, L., Matera, M. G., Cazzola, M., Castaldo, G., & Bianco, A. (2020) · Lung · doi:10.1007/s00408-020-00408-4 · Cited by 481
Syncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106267 · Cited by 462
“ACE2 cleavage by TMPRSS2 and other cellular proteases was previously reported and proposed to generate a receptor enhancing viral uptake (Haga et al , 2008; Shulla et al , 2011; Heurich et al , 2014).”
New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis
Hou, Y., Zhao, J., Martin, W., Kallianpur, A., Chung, M. K., Jehi, L., Sharifi, N., Erzurum, S., Eng, C., & Cheng, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01673-z · Cited by 438
Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Drucker, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa011 · Cited by 399
ACE2, Much More Than Just a Receptor for SARS-COV-2
Samavati, L., & Uhal, B. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00317 · Cited by 364
Kreutz, R., Algharably, E. A. E.-H., Azizi, M., Dobrowolski, P., Guzik, T., Januszewicz, A., Persu, A., Prejbisz, A., Riemer, T. G., Wang, J.-G., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa097 · Cited by 357
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00653-w · Cited by 339
Syncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020107405 · Cited by 333
Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion
Papa, G., Mallery, D. L., Albecka, A., Welch, L. G., Cattin-Ortolá, J., Luptak, J., Paul, D., McMahon, H. T., Goodfellow, I. G., Carter, A., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009246 · Cited by 329
Sex differences in severity and mortality from COVID-19: are males more vulnerable?
Pradhan, A., & Olsson, P.-E. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00330-7 · Cited by 313
Kirtipal, N., Bharadwaj, S., & Kang, S. G. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104502 · Cited by 306
Overview of lethal human coronaviruses
Chen, B., Tian, E.-K., He, B., Tian, L., Han, R., Wang, S., Xiang, Q., Zhang, S., El Arnaout, T., & Cheng, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0190-2 · Cited by 300
TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections
Shen, L. W., Mao, H. J., Wu, Y. L., Tanaka, Y., & Zhang, W. (2017) · Biochimie · doi:10.1016/j.biochi.2017.07.016 · Cited by 285
Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?
Pique-Regi, R., Romero, R., Tarca, A. L., Luca, F., Xu, Y., Alazizi, A., Leng, Y., Hsu, C.-D., & Gomez-Lopez, N. (2020) · eLife · doi:10.7554/elife.58716 · Cited by 283
Moustaqil, M., Ollivier, E., Chiu, H.-P., Van Tol, S., Rudolffi-Soto, P., Stevens, C., Bhumkar, A., Hunter, D. J. B., Freiberg, A. N., Jacques, D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1870414 · Cited by 283
Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2
Salamanna, F., Maglio, M., Landini, M. P., & Fini, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.594495 · Cited by 281
COVID-19, Renin-Angiotensin System and Endothelial Dysfunction
Amraei, R., & Rahimi, N. (2020) · Cells · doi:10.3390/cells9071652 · Cited by 270
ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
Zipeto, D., Palmeira, J. D. F., Argañaraz, G. A., & Argañaraz, E. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576745 · Cited by 267
Benetti, E., Tita, R., Spiga, O., Ciolfi, A., Birolo, G., Bruselles, A., Doddato, G., Giliberti, A., Marconi, C., Musacchia, F., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-0691-z · Cited by 263
Planas, D., Staropoli, I., Michel, V., Lemoine, F., Donati, F., Prot, M., Porrot, F., Guivel-Benhassine, F., Jeyarajah, B., Brisebarre, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46490-7 · Cited by 263
Onabajo, O. O., Banday, A. R., Stanifer, M. L., Yan, W., Obajemu, A., Santer, D. M., Florez-Vargas, O., Piontkivska, H., Vargas, J. M., Ring, T. J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00731-9 · Cited by 261
Samuel, R. M., Majd, H., Richter, M. N., Ghazizadeh, Z., Zekavat, S. M., Navickas, A., Ramirez, J. T., Asgharian, H., Simoneau, C. R., Bonser, L. R., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.11.009 · Cited by 261
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
Dong, M., Zhang, J., Ma, X., Tan, J., Chen, L., Liu, S., Xin, Y., & Zhuang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110678 · Cited by 259
Datta, P. K., Liu, F., Fischer, T., Rappaport, J., & Qin, X. (2020) · Theranostics · doi:10.7150/thno.48076 · Cited by 257
Iwasaki, M., Saito, J., Zhao, H., Sakamoto, A., Hirota, K., & Ma, D. (2021) · Inflammation · doi:10.1007/s10753-020-01337-3 · Cited by 229
Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation
Fraser, B. J., Beldar, S., Seitova, A., Hutchinson, A., Mannar, D., Li, Y., Kwon, D., Tan, R., Wilson, R. P., Leopold, K., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01059-7 · Cited by 218
Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19
Alon, R., Sportiello, M., Kozlovski, S., Kumar, A., Reilly, E. C., Zarbock, A., Garbi, N., & Topham, D. J. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00470-2 · Cited by 197
Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking
Engin, A. B., Engin, E. D., & Engin, A. (2020) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2020.103411 · Cited by 187
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19
Bernard, I., Limonta, D., Mahal, L., & Hobman, T. (2020) · Viruses · doi:10.3390/v13010029 · Cited by 183
“However, other studies did not find evidence supporting the role of ADAM17 in SARS-CoV-1 entry [136,140].”
ResultAndrogen sensitivity gateway to COVID‐19 disease severity
Wambier, C. G., Goren, A., Vaño‐Galván, S., Ramos, P. M., Ossimetha, A., Nau, G., Herrera, S., & McCoy, J. (2020) · Drug Development Research · doi:10.1002/ddr.21688 · Cited by 164
Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic
Pozzilli, P., & Lenzi, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154252 · Cited by 161
“TMPRSS2 may also cleave ACE2 for augmented viral entry [23].”
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Devaux, C. A., & Camoin-Jau, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042200 · Cited by 20
“Finally, the Arg652 of ACE2 is a target for the catalytic site of proteases ADAM17 and TMPRSS2, which leads to the shedding of a soluble form of ACE2 (sACE2; Heurich et al., 2014; Lanjanian et al., 2021).”
BackgroundKahveci-Türköz, S., Bläsius, K., Wozniak, J., Rinkens, C., Seifert, A., Kasparek, P., Ohm, H., Oltzen, S., Nieszporek, M., Schwarz, N., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04783-y · Cited by 17
Molecular basis of proteolytic cleavage regulation by the extracellular matrix receptor dystroglycan
Anderson, M. J. M., Hayward, A. N., Smiley, A. T., Shi, K., Pawlak, M. R., Aird, E. J., Grant, E., Greenberg, L., Aihara, H., Evans, R. L., et al. (2024) · Structure · doi:10.1016/j.str.2024.08.019 · Cited by 5
Metadata
- Authors
- Heurich, A., Hofmann-Winkler, H., Gierer, S., Liepold, T., Jahn, O., & Pöhlmann, S.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2014-01-15
- Volume
- 88
- Issue
- 2
- Pages
- 1293-1307
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W1998964868
- Cited by
- 881
- References
- 60
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.